Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Ascendis Pharma Ads (ASND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon(TM) hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth Hormone

- Provides real-world experience for switching pediatric growth hormone deficiency subjects one to 17 years old from daily growth hormone to once-weekly TransCon hGH -

ASND : 128.96 (+3.46%)
Ascendis Pharma A/S Announces First Quarter 2019 Financial Results and Business Update Conference Call on May 30

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will hold a conference...

ASND : 128.96 (+3.46%)
Ascendis Pharma A/S Announces Participation in the Bank of America Merrill Lynch 2019 Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will participate...

ASND : 128.96 (+3.46%)
Ascendis Pharma A/S Reports Full Year 2018 Financial Results

- Rare disease endocrinology pipeline continues to advance, with

ASND : 128.96 (+3.46%)
Ascendis Pharma A/S Sponsored ADR to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / April 3, 2019 / Ascendis Pharma A/S Sponsored ADR (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on April 3, 2019 at 4:30...

ASND : 128.96 (+3.46%)
Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technology to address unmet medical needs, today announced that the company will hold a conference...

ASND : 128.96 (+3.46%)
Ascendis Pivotal Growth Hormone Deficiency Study Data Positive

Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.

ASND : 128.96 (+3.46%)
RHHBY : 34.0000 (+0.74%)
PFE : 41.95 (+0.07%)
SNY : 42.28 (+0.40%)
Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technology to address unmet medical needs, today announced a study evaluating impact of hypoparathyroidism...

ASND : 128.96 (+3.46%)
Ascendis Pharma Announces Phase 3 heiGHt Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon(TM) hGH to a Daily Growth Hormone

- Oral presentation of results in pediatric growth hormone deficiency on behalf of investigators at ENDO 2019 -

ASND : 128.96 (+3.46%)
What Makes Ascendis Pharma A/S (ASND) a New Buy Stock

Ascendis Pharma A/S (ASND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ASND : 128.96 (+3.46%)
Report: Exploring Fundamental Drivers Behind Manulife Financial, Fidelity National Financial, Heritage-Crystal Clean, Ericsson, Ascendis Pharma A/S, and Astec Industries -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Manulife Financial Corp (NYSE:MFC),...

HCCI : 27.24 (-2.12%)
ASND : 128.96 (+3.46%)
ERIC : 10.03 (+3.19%)
MFC : 17.34 (+1.11%)
ASTE : 29.76 (+0.20%)
FNF : 38.85 (+0.23%)
Company News For Mar 5, 2019

Companies in the news are; PLCE, BIIB, NITE, ASND and TAK

ASND : 128.96 (+3.46%)
NITE : 25.47 (-0.12%)
PLCE : 102.38 (+1.37%)
BIIB : 227.06 (-0.89%)
TAK : 17.71 (+1.61%)
Ascendis Pharma Reaches Analyst Target Price

In recent trading, shares of Ascendis Pharma A/S have crossed above the average analyst 12-month target price of $85.38, changing hands for $120.60/share. When a stock reaches the target an analyst has...

ASND : 128.96 (+3.46%)
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technology to address unmet medical needs, today announced that it has commenced an underwritten...

JPM : 109.71 (+0.98%)
MS : 42.96 (+0.59%)
ASND : 128.96 (+3.46%)
Ascendis Pharma Announces Once-weekly TransCon(TM) Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency

- TransCon hGH demonstrated comparable safety and tolerability to a daily hGH -

ASND : 128.96 (+3.46%)
Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for Achondroplasia

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technology to address significant unmet medical needs, today announced that the U.S. Food and Drug...

ASND : 128.96 (+3.46%)
Recent Analysis Shows Intel, Gilead Sciences, Amdocs, Ascendis Pharma A/S, Hill-Rom, and Ingevity Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Intel Corporation (NASDAQ:INTC),...

NGVT : 87.43 (+1.36%)
INTC : 44.57 (+0.09%)
ASND : 128.96 (+3.46%)
HRC : 97.31 (+0.77%)
GILD : 66.89 (-0.42%)
DOX : 60.49 (-0.43%)
Ascendis Pharma Files IND for Hypoparathyroidism Candidate

Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.

GALT : 4.03 (+0.50%)
ASND : 128.96 (+3.46%)
RHHBY : 34.0000 (+0.74%)
SNY : 42.28 (+0.40%)
Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technology to address significant unmet medical needs, today announced the filing of an investigational...

ASND : 128.96 (+3.46%)
All You Need to Know About Ascendis Pharma A/S (ASND) Rating Upgrade to Buy

Ascendis Pharma A/S (ASND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ASND : 128.96 (+3.46%)

Van Meerten Stock Picks

NextEra Energy - Large Cap Pick
The Large Cap Pick of the Day is electric utility company NextEra Energy(NEE).
NEE -0.16
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar